Five Prime Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Five Prime Therapeutics, Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$84.33 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2021-03-22
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$20.85M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$26.42M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$16.94M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-03-31 was -$20.12M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$84.33M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$137.20M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$140.45M.
- Five Prime Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$150.22M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$20.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$47.27M derived: sum of 2 quarters · filed 2021-03-22 | -$64.21M derived: sum of 3 quarters · filed 2021-03-22 | -$84.33M 10-K · filed 2021-03-22 |
| 2020-09-30 | -$26.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | -$43.36M derived: sum of 2 quarters · filed 2020-11-03 | -$63.48M 10-Q · filed 2020-11-03 | -$94.83M derived: sum of 4 quarters · filed 2021-03-22 |
| 2020-06-30 | -$16.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$37.05M 10-Q · filed 2020-08-06 | -$68.41M derived: sum of 3 quarters · filed 2021-03-22 | -$104.48M derived: sum of 4 quarters · filed 2021-03-22 |
| 2020-03-31 | -$20.12M 10-Q · filed 2020-05-07 | -$51.47M derived: sum of 2 quarters · filed 2021-03-22 | -$87.54M derived: sum of 3 quarters · filed 2021-03-22 | -$121.93M derived: sum of 4 quarters · filed 2021-03-22 |
| 2019-12-31 | -$31.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$67.43M derived: sum of 2 quarters · filed 2021-03-22 | -$101.82M derived: sum of 3 quarters · filed 2021-03-22 | -$137.20M 10-K · filed 2021-03-22 |
| 2019-09-30 | -$36.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | -$70.46M derived: sum of 2 quarters · filed 2020-11-03 | -$105.84M 10-Q · filed 2020-11-03 | -$144.60M derived: sum of 4 quarters · filed 2021-03-22 |
| 2019-06-30 | -$34.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$69.78M 10-Q · filed 2020-08-06 | -$108.53M derived: sum of 3 quarters · filed 2021-03-22 | -$155.77M derived: sum of 4 quarters · filed 2021-03-22 |
| 2019-03-31 | -$35.38M 10-Q · filed 2020-05-07 | -$74.14M derived: sum of 2 quarters · filed 2021-03-22 | -$121.38M derived: sum of 3 quarters · filed 2021-03-22 | -$155.44M derived: sum of 4 quarters · filed 2021-03-22 |
| 2018-12-31 | -$38.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$86.00M derived: sum of 2 quarters · filed 2021-03-22 | -$120.06M derived: sum of 3 quarters · filed 2021-03-22 | -$140.45M 10-K · filed 2021-03-22 |
| 2018-09-30 | -$47.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$81.30M derived: sum of 2 quarters · filed 2019-11-06 | -$101.69M 10-Q · filed 2019-11-06 | -$130.91M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$34.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$54.45M 10-Q · filed 2019-08-08 | -$83.66M derived: sum of 3 quarters · filed 2020-02-27 | -$126.94M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$20.39M 10-Q · filed 2019-05-09 | -$49.60M derived: sum of 2 quarters · filed 2020-02-27 | -$92.88M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$29.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$72.49M derived: sum of 2 quarters · filed 2020-02-27 | -$150.22M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$43.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$121.01M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$77.73M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$65.70M 10-K · filed 2019-02-26 | |||
| 2013-12-31 | -$28.87M 10-K · filed 2014-03-26 | |||
| 2012-12-31 | -$27.59M 10-K · filed 2014-03-26 | |||
| 2011-12-31 | $19.71M 10-K · filed 2014-03-26 |